Gensia Pharmaceuticals Inc., Marion Merrell Dow Inc. deal

MMD decided not to exercise its option on GNSA's adenosine compound GP-1-531 for cardiovascular use. MMD spokesperson Charles Rouse told BioCentury the compound didn't fit the company's "strategic profile."

MMDI licensed another adenosine regulating agent, GP-1-468-3, under its agreement with GNSA and GNSA's Aramed R&D vehicle (ARAMZ), which is scheduled to begin Phase I testing in the first half of 1994. ...